© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
NEWS |
For Ovarian Cancer, An Optimal Treatment Remains To Be Found
| The first 10% of the full text of this article appears below. |
The search for more effective treatments for advanced ovarian cancer continues as results achieved with current strategies leave considerable room for improvement.
"Progression-free survival, even in optimally debulked patients, is less than 2 years," British oncologist Stanley Kaye, M.D., said during an educational symposium at the European Cancer Conference in Copenhagen in September. "We need to do better. The majority of patients will still have died by 5 years."
Ongoing investigations focus in large part on the development of more effective chemotherapy regimens for primary treatment and relapsed disease. Early clinical evaluations of chemotherapy for ovarian cancer suggested three principles that remain inherent to treatment strategies today: immediate
Second-Line Therapy
Role of Surgery
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Marchini, P. Mariani, G. Chiorino, E. Marrazzo, R. Bonomi, R. Fruscio, L. Clivio, A. Garbi, V. Torri, M. Cinquini, et al. Analysis of Gene Expression in Early-Stage Ovarian Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7850 - 7860. [Abstract] [Full Text] [PDF] |
||||
